Microbiome Affected by Babies’ Delivery Method, but Long-Term Effects Remain Unknown

GEN | September 19, 2019

The role of delivery method on the acquisition of a newborn’s gut microbiome has been an ongoing, controversial topic. Although vaginal and cesarean section deliveries have been previously shown to result in differences, the significance between the two in infancy, into childhood and beyond, has not been established. A new study—the largest of its kind—has been published through the Baby Biome Study. The researchers from the Wellcome Sanger Institute, UCL, and the University of Birmingham found that babies born vaginally received most of their gut bacteria from their mother, while babies born through cesarean section are colonized less by bacteria found in their mothers and, instead, have more bacteria representative of the hospital environment. The exact role of the baby’s gut bacteria is unclear and it isn’t known if these differences at birth will have any effect on later health. The researchers found the differences in gut bacteria between vaginally born and cesarean delivered babies largely evened out by one year old, but large follow-up studies are needed to determine if the early differences influence health outcomes.

Spotlight

And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis. Here is an infographic-based overview of some of the target areas that European start-ups and publicly listed companies are working on.

Spotlight

And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis. Here is an infographic-based overview of some of the target areas that European start-ups and publicly listed companies are working on.

Related News

INDUSTRIAL IMPACT

Axion BioSystems Expands Operations with Acquisition of M-Solv Manufacturing Limited

Axion BioSystems | February 03, 2022

Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies, announces the acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, a subsidiary of M-Solv Ltd. The creation of the new division, called Axion BioSystems Manufacturing, UK, Ltd., cements the six-year partnership between the companies and positions Axion for continued growth and innovation. “The need to control the supply chain has never been more important. This vertical integration not only ensures that our customers have the products they need to conduct critical biomedical research; it also allows us to advance assay plate technologies more rapidly to meet the increasingly complex scientific demands of our users.” Tom O’Brien, CEO of Axion BioSystems Since 2017, M-Solv has supplied Atlanta-based Axion BioSystems with high-resolution proprietary printed electronics circuits, a critical consumable used in Axion’s flagship Maestro Pro multielectrode array benchtop instrument. The Maestro Pro system provides pharmaceutical companies, biotechnology firms, and research scientists with a state-of-the-art cell analysis platform for disease modeling and drug discovery. Integrating M-Solv’s development and manufacturing team represents a key step forward in Axion’s continuous efforts to streamline manufacturing and continue its leadership in this space. “The M-Solv manufacturing team is proud to have played a role supporting Axion’s growth over the last six years,” said Phil Rumsby, CEO of M-Solv Manufacturing Limited. “Now, as part of the Axion Group, we are looking forward to working together even more closely to grow this part of our business as we develop the next generation of bioelectronic assay consumables. Alongside our biosensor business, we will continue to maintain and grow our strong position in touch-panel devices.” About Axion BioSystems Axion BioSystems is a leading life science tools company focused on developing and commercializing label-free, bioelectronic assays used to study the function of live cells in vitro for drug discovery and disease modeling. The team at Axion BioSystems is dedicated to continuing the advancement of bioelectronic assay technology that enables the understanding of biological complexity outside of the body. Axion BioSystems is headquartered in Atlanta, Georgia, USA, and also has an office in Shanghai, China. Axion has more than 90 employees across its current locations. About M-Solv Manufacturing Limited M-Solv Manufacturing Limited develops and manufactures unique printed electronics, making industrial-grade capacitive touch panels and biosensors at its foundry in Oxford, UK. Prior to acquisition by Axion, the company was part of the M-Solv Ltd. group of companies. M-Solv Ltd. is a world leader in the supply of advanced laser and inkjet digital production tools with teams based in Taiwan, Hong Kong, and Shenzhen, and is ultimately owned by the Hong Kong-based CN Innovations Group.

Read More

MEDTECH

Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

Alloy Therapeutics | December 10, 2021

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and will hire additional computational scientists and developers as it grows with the Alloy network. The deepCDR engine combines deep sequencing and deep learning methods with a proprietary mammalian display process to select from a wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles. The company was a spinoff of ETH Zurich and Department of Biosystems Science and Engineering and was founded by Sai Reddy, an Associate Professor of Systems and Synthetic Immunology at ETH Zurich and an expert in immunogenomics and machine learning-guided protein engineering. “Uniting deepCDR and Alloy reflects our conviction in the power of network effects and scientific collaboration—together our companies’ capabilities are amplified to better serve the global scientific community in its pursuit of finding the best medicines for patients. Our network of partners will be able to work with deepCDR’s machine learning engine in a way that otherwise would have been cost prohibitive or inaccessible. The ongoing technology improvements will enhance the output of Alloy platforms and Alloy Discovery Services for the benefit of all of our drug discovery partners.” Alloy Therapeutics CEO and Founder Errik Anderson DeepCDR’s technology will strengthen Alloy Discovery Services capabilities with patent-pending machine learning-powered antibody repertoire screening, in silico library screening, and mammalian display. DeepCDR thoughtfully integrates wet lab antibody screening and characterization with the computational tools to enable a powerful learning loop generating real world results. The deepCDR team will form Alloy’s new Basel, Switzerland operations and comprises expertise in antibody engineering and optimization, bioinformatics, and in silico library screening. “We are thrilled to join Alloy on its mission of empowering scientific entrepreneurs and democratizing foundational drug discovery capabilities,” said deepCDR founder Sai Reddy. “The data sets and infrastructure within Alloy unlock powerful new opportunities for the deepCDR technology and team that will in turn enable us to help drug discovery teams more effectively and efficiently find the best antibody candidates. We envision a future where Alloy will be a leader in unifying real-world patient, genomic, and protein sequence data to empower integrated AI and ML drug discovery and engineering.” About Alloy Therapeutics Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma. Alloy’s lead offering, the ATX-Gx™ platform, is a human therapeutic antibody discovery platform consisting of a growing suite of proprietary transgenic mice strains. Alloy is a leader in bispecific antibody discovery and engineering services, utilizing its proprietary ATX-CLC common light chain platform integrating novel transgenic mice and phage display. Alloy is headquartered in Boston, MA with labs in Cambridge, UK; Basel, CH; San Francisco, CA; and Athens, GA. As a reflection of Alloy’s relentless commitment to the scientific community, Alloy reinvests 100% of its revenue in innovation and access to innovation.

Read More

Lesaffre and Recombia Biosciences Announces Strategic Partnership to Advance Innovative Gene Editing Technology

Recombia Biosciences | November 02, 2020

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in parallel, combined with laboratory automation, is expected to exponentially accelerate development of projects in the areas of health, the environment, and energy. The partnership also signifies Lesaffre's entry into the world of Synthetic Biology, considered to be the major biotechnological opportunity of this decade. Recombia Biosciences was founded by three Stanford University researchers in 2019 as a spin-off from the prestigious Stanford Genome Technology Center (SGTC). Recombia's technologies are based upon techniques that increase the efficiency of genome editing and enable engineering of yeast at very high throughput. The strategic collaboration with Lesaffre aims to advance Recombia's proprietary gene editing technologies to identify new yeast strains, discover novel yeast physiology of industrial relevance and optimize the production of biosourced ingredients and biofuels.

Read More